CYP4A11 Antibody

What is CYP4A11 and why is it important to study in human metabolism?

CYP4A11 is a cytochrome P450 enzyme primarily involved in ω-hydroxylation of fatty acids. It plays a significant role in fatty acid metabolism and has been implicated in the development of nonalcoholic fatty liver disease (NAFLD). The enzyme metabolizes fatty acids to promote the production of reactive oxygen species (ROS), potentially accelerating NAFLD progression . CYP4A11 is particularly important in understanding oxidative stress mechanisms and inflammatory responses in metabolic disorders, as its expression correlates strongly with lipid peroxidation levels in patients with NAFLD . Research techniques using CYP4A11 antibodies are essential for investigating these pathways in hepatic and vascular diseases.

How does CYP4A11 expression differ between normal subjects and patients with metabolic disorders?

CYP4A11 expression shows significant differences between healthy individuals and those with metabolic disorders, particularly NAFLD. Clinical studies have demonstrated that plasma CYP4A11 levels are significantly elevated in NAFLD patients compared to healthy controls . This elevation correlates with increased lipid peroxidation products, suggesting a mechanistic relationship. In a clinical study, the following parameters were observed:

These differences in metabolic parameters parallel the increased CYP4A11 expression, with a strong correlation (r=0.86) between CYP4A11 levels and lipid peroxidation markers in NAFLD patients .

What techniques are most effective for detecting CYP4A11 protein expression in biological samples?

Multiple techniques have proven effective for detecting CYP4A11 protein expression, with Western blot analysis and ELISA being the most commonly employed. For Western blot analysis, homogenates should be prepared using radioimmunoprecipitation assay (RIPA) buffer, and proteins (20-40 μg) separated on a 14% Tris-glycine gel . The recommended antibody dilution for CYP4A11 primary antibody is 1:500, followed by incubation with an anti-rabbit horseradish peroxidase secondary antibody and development by enhanced chemiluminescence . For plasma samples, ELISA has been effectively used to quantify CYP4A11 levels in clinical studies of NAFLD patients . When detecting CYP4A11 in cell culture models such as HepG2 cells, Western blotting can be coupled with gene expression analysis to confirm protein levels after experimental manipulations .

How can researchers differentiate between CYP4A11 and other closely related cytochrome P450 family members?

Differentiating between CYP4A11 and related cytochrome P450 family members requires careful primer design for gene expression analysis and selection of specific antibodies. For PCR-based differentiation, researchers should use primers specifically designed for distinct regions of CYP4A11. The recommended primers for CYP4A11 are: forward 5′-AATTTGCCATGAACGAACGAGCTGA-3′ and reverse 5′-TTTCCAAAGGCCACAAGG-3′, which yield a 500 bp product . For distinguishing CYP4A11 from the highly similar CYP4A22, the following primers are recommended for CYP4A22: forward 5′-AATTTGCCATGAACCAGCTGA-3′ and reverse 5′-GGTCCTTGTCTTCACAAGGG-3′, yielding a 172 bp product . When using antibodies, researchers should validate specificity through comparative analysis with recombinant proteins or knockdown experiments, as Western blot analysis has confirmed that endothelial progenitor cells (EPCs) express CYP4A11/22 protein .

What role does CYP4A11 play in the pathogenesis of nonalcoholic fatty liver disease?

CYP4A11 plays a multifaceted role in NAFLD pathogenesis through several interconnected mechanisms. It metabolizes fatty acids to promote ROS production, which contributes to oxidative stress in hepatocytes . In free fatty acid (FFA)-stimulated HepG2 cells, CYP4A11 expression increases alongside elevated ROS content, suggesting a direct relationship between fatty acid metabolism and oxidative damage . The enzyme also influences inflammatory pathways, as demonstrated by the upregulation of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in response to CYP4A11 overexpression . Research using CYP4A11 inducers like clofibrate showed aggravated cell damage in FFA-treated cells, while the inhibitor HET0016 attenuated apoptosis, further confirming CYP4A11's role in disease progression . These findings indicate that CYP4A11 acts as a crucial mediator in the progression from simple steatosis to steatohepatitis by promoting oxidative stress and inflammatory responses.

How does manipulation of CYP4A11 expression affect oxidative stress markers in hepatic cell models?

Manipulation of CYP4A11 expression has direct and measurable effects on oxidative stress markers in hepatic cell models. Overexpression of CYP4A11 through transfection with pcDNA3.1-CYP4A11 significantly increases ROS levels and malondialdehyde (MDA) content in HepG2 cells treated with free fatty acids, while simultaneously decreasing superoxide dismutase (SOD) levels . Conversely, inhibition of CYP4A11 with HET0016 significantly reduces intracellular ROS production compared to cells treated with the CYP4A11 inducer clofibrate . Silencing CYP4A11 expression using siRNA further confirms these effects, demonstrating reduced oxidative stress markers. These manipulations reveal that CYP4A11 expression directly modulates the oxidative balance in hepatocytes, with higher expression promoting oxidative damage and lower expression offering protective effects against ROS-mediated cellular injury .

What is the relationship between CYP4A11 activity and inflammatory cytokine production in cellular models?

CYP4A11 activity has a significant positive correlation with inflammatory cytokine production in cellular models. Experimental evidence shows that overexpression of CYP4A11 in HepG2 cells through pcDNA3.1-CYP4A11 transfection significantly increases the mRNA expression of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in response to free fatty acid treatment . Conversely, when CYP4A11 is silenced using siRNA-CYP4A11, the expression levels of these inflammatory cytokines are markedly inhibited . The mechanism underlying this relationship appears to involve ROS production and subsequent activation of the NF-κB signaling pathway. CYP4A11-induced ROS and lipid peroxides can activate NF-κB, which then promotes the transcription of inflammatory cytokines . This relationship forms a critical link between lipid metabolism, oxidative stress, and inflammatory responses in fatty liver disease progression.

How does CYP4A11 influence the NF-κB signaling pathway in metabolic disorders?

CYP4A11 exerts significant influence on the NF-κB signaling pathway, primarily through modulation of phosphorylated p65 levels. Western blot analyses have demonstrated that overexpression of CYP4A11 increases p-p65 levels compared to vector controls, indicating enhanced NF-κB pathway activation . Conversely, CYP4A11 silencing with siRNA inhibits p-p65 expression compared to siRNA-NC controls . The mechanism connecting CYP4A11 to NF-κB activation involves ROS production—CYP4A11 metabolizes fatty acids, which increases cellular ROS levels, and these reactive species can activate the NF-κB pathway . The interaction between ROS and NF-κB signaling is complex, with ROS capable of both activating and inhibiting NF-κB depending on cellular context and ROS levels . This relationship creates a feedback loop where CYP4A11-mediated oxidative stress enhances inflammatory responses through NF-κB activation, which can further exacerbate metabolic dysfunction in disorders like NAFLD.

What experimental approaches can resolve contradictory findings regarding CYP4A11 function?

Resolving contradictory findings regarding CYP4A11 function requires multi-faceted experimental approaches that address methodological variabilities. First, researchers should employ both gain-of-function (overexpression) and loss-of-function (silencing/inhibition) strategies within the same experimental system, as demonstrated in studies using both pcDNA3.1-CYP4A11 transfection and siRNA-CYP4A11 knockdown . Second, validation across multiple cell types is crucial—findings in HepG2 cells should be compared with primary hepatocytes or other relevant cell types like endothelial progenitor cells that express CYP4A11/22 . Third, researchers should measure multiple downstream effects simultaneously (oxidative stress markers, inflammatory cytokines, and signaling pathway activation) to establish causative relationships rather than correlations . Additionally, careful consideration of experimental conditions including fatty acid concentrations, exposure times, and culture conditions is essential, as these factors can significantly influence CYP4A11 expression and function. Finally, translational validation using patient samples with appropriate clinical parameters (as shown in Table I from the NAFLD study) can help connect in vitro findings to clinical relevance .

What are the optimal conditions for Western blot analysis of CYP4A11 protein?

Optimal Western blot analysis of CYP4A11 protein requires careful attention to several key parameters. Sample preparation should involve homogenization in radioimmunoprecipitation assay (RIPA) buffer to ensure adequate protein extraction . Protein separation is most effective using a 14% Tris-glycine gel, which provides optimal resolution for CYP4A11 (approximately 50-52 kDa) . For primary antibody incubation, a 1:500 dilution of CYP4A11 antibody (such as those from RDI Division of Fitzgerald Industries) has been successfully employed . Detection should utilize anti-rabbit horseradish peroxidase secondary antibody with enhanced chemiluminescence development . To ensure accurate quantification, researchers should strip and reprobe membranes with antibodies against housekeeping proteins like β-actin as loading controls . For challenging samples with low CYP4A11 expression, longer exposure times or more sensitive detection systems may be required. When comparing expression levels across different conditions, normalization to both loading controls and baseline expression is essential for accurate interpretation of results .

What are the recommended protocols for RT-PCR analysis of CYP4A11 gene expression?

For optimal RT-PCR analysis of CYP4A11 gene expression, researchers should follow these methodological steps. RNA extraction should be performed using TRIzol reagent with DNase treatment to remove genomic DNA contamination . RNA concentration should be measured by absorbance at 260 nm, with 1 μg of RNA reverse-transcribed using a SuperScript first-strand synthesis system . For PCR amplification of CYP4A11, the recommended primers are: forward 5′-AATTTGCCATGAACGAACGAGCTGA-3′ and reverse 5′-TTTCCAAAGGCCACAAGG-3′, which yield a 500 bp product . Amplification conditions should include 95°C for 3 min initial denaturation, followed by 40 cycles of 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min, with a final extension at 72°C for 10 min . Products should be separated by electrophoresis on 1% agarose gels for visualization . For quantitative analysis, real-time PCR can be performed using a LightCycler system with SYBR Green chemistry, with cycling conditions of 95°C for 10 min, followed by 55 cycles of 95°C for 10 s, 55°C for 5 s, and 72°C for 15 s . Data analysis should employ the 2^(-ΔΔCT) method to calculate relative changes in gene expression .

How can researchers effectively induce or inhibit CYP4A11 in cellular models for functional studies?

Researchers can effectively modulate CYP4A11 activity in cellular models through both pharmacological and genetic approaches. For pharmacological induction, clofibrate has been successfully used to increase CYP4A11 expression in HepG2 cells, enhancing ROS production and oxidative stress markers . Conversely, HET0016 serves as an effective inhibitor of CYP4A11, attenuating ROS production and oxidative damage in FFA-treated cells . For genetic manipulation, transfection with pcDNA3.1-CYP4A11 provides robust overexpression, with significant increases in both mRNA and protein levels as confirmed by Western blot and RT-qPCR . For gene silencing, siRNA-CYP4A11 effectively reduces expression, with corresponding decreases in inflammatory cytokine production and NF-κB pathway activation . When designing these experiments, researchers should include appropriate controls: empty vector for overexpression studies, negative control siRNA for knockdown experiments, and vehicle controls for pharmacological interventions . Validation of successful manipulation should include both mRNA and protein expression analysis to confirm the intended effects on CYP4A11 levels.

What cellular models are most appropriate for investigating CYP4A11 function in disease contexts?

The selection of appropriate cellular models for CYP4A11 research depends on the specific disease context under investigation. For nonalcoholic fatty liver disease (NAFLD) studies, HepG2 human hepatoma cells have proven effective when treated with free fatty acids to mimic steatosis . This model successfully recapitulates the increased CYP4A11 expression, ROS production, and inflammatory responses observed in clinical NAFLD samples . For vascular and endothelial research, endothelial progenitor cells (EPCs) isolated from umbilical cord blood express CYP4A11/22 protein as confirmed by Western blot, making them suitable for studies of CYP4A11 in vascular function . These cells can be isolated using CD133+ markers and maintained in appropriate growth medium containing stem cell factor, FLT3, and thrombopoietin . For comparative studies, mesenchymal stem cells (MSCs) may serve as controls or alternative models . When working with these models, researchers should verify baseline CYP4A11 expression levels and response to modulators before proceeding with mechanistic studies, as expression can vary with culture conditions and passage number.

What analytical methods should be used to assess the downstream effects of CYP4A11 activity?

Comprehensive assessment of CYP4A11 downstream effects requires multiple analytical approaches targeting oxidative stress, inflammatory responses, and signaling pathway activation. For oxidative stress evaluation, intracellular ROS content should be measured by fluorescence detection methods in cell culture models . Measurement of malondialdehyde (MDA) levels provides quantification of lipid peroxidation, while superoxide dismutase (SOD) activity assays assess antioxidant capacity . For inflammatory responses, RT-qPCR analysis of TNF-α, IL-1β, and IL-6 mRNA expression provides sensitive detection of pro-inflammatory cytokine production . Protein levels of these cytokines can be confirmed by ELISA or Western blot. To assess signaling pathway activation, Western blot analysis of phosphorylated p65 levels effectively monitors NF-κB pathway activity . For clinical samples, plasma lipid peroxidation (LPO) levels measured by ELISA correlate strongly with CYP4A11 expression (r=0.86) . When implementing these methods, researchers should include appropriate positive and negative controls, and when possible, utilize both genetic manipulation (overexpression/silencing) and pharmacological approaches (induction/inhibition) to confirm that observed effects are specifically attributable to CYP4A11 activity.

How can researchers address antibody cross-reactivity issues between CYP4A11 and related isoforms?

Addressing CYP4A11 antibody cross-reactivity requires a systematic validation approach. Researchers should first conduct epitope analysis of available antibodies, preferring those targeting unique regions of CYP4A11 not shared with CYP4A22 or other family members . Validation should include Western blot comparison using recombinant proteins of CYP4A11 and related isoforms to establish specificity profiles. When cross-reactivity cannot be eliminated, complementary genetic approaches become essential. Researchers should perform parallel gene expression analysis using the highly specific primers: CYP4A11 (forward 5′-AATTTGCCATGAACGAACGAGCTGA-3′ and reverse 5′-TTTCCAAAGGCCACAAGG-3′) versus CYP4A22 (forward 5′-AATTTGCCATGAACCAGCTGA-3′ and reverse 5′-GGTCCTTGTCTTCACAAGGG-3′) . Another effective strategy involves siRNA knockdown targeting specific isoforms, followed by antibody detection to determine which signals are reduced. For critical experiments, researchers should consider using multiple antibodies targeting different epitopes and correlating results across detection methods. When reporting findings, specificity limitations should be explicitly acknowledged, using terminology like "CYP4A11/22" when complete differentiation cannot be assured .

How should researchers interpret conflicting data regarding CYP4A11 expression across different tissue types?

Interpretation of conflicting CYP4A11 expression data across tissues requires careful consideration of several factors. First, examine isolation and detection methods—studies using different techniques (Western blot, PCR, immunohistochemistry) may yield varying results based on methodological sensitivities . Second, consider tissue-specific regulatory mechanisms that may cause CYP4A11 to be differentially expressed or regulated across cell types. Third, evaluate pathological states—CYP4A11 expression significantly increases in NAFLD compared to normal liver, suggesting disease-dependent regulation . Fourth, account for genetic variants and polymorphisms that may impact expression levels or antibody binding across different study populations. To resolve conflicts, researchers should implement standardized protocols across tissue types, use multiple detection methods in parallel, and explicitly report normalization strategies. Where possible, single-cell analysis techniques can help determine if apparent differences reflect true biological variation or technical artifacts. Finally, careful citation practices acknowledging methodological differences between studies can help contextualize seemingly contradictory findings within the broader literature.

How can CYP4A11 antibodies be used to investigate the relationship between oxidative stress and inflammatory pathways?

CYP4A11 antibodies serve as powerful tools for investigating the oxidative stress-inflammation axis in research. Researchers can employ dual immunofluorescence staining with CYP4A11 antibodies alongside markers of oxidative damage (8-OHdG, 4-HNE) to co-localize enzyme expression with oxidative stress in tissue samples. In cell culture models, Western blot analysis using CYP4A11 antibodies can track protein expression changes following experimental manipulations, correlating these with ROS measurements and inflammatory cytokine production . Immunoprecipitation with CYP4A11 antibodies followed by mass spectrometry can identify novel protein-protein interactions that may mediate cross-talk between oxidative and inflammatory pathways. For mechanistic studies, researchers can use CYP4A11 antibodies to monitor protein levels after modulating the NF-κB pathway, as CYP4A11 overexpression increases phosphorylated p65 levels while CYP4A11 silencing reduces p-p65 expression . ChIP assays using antibodies against NF-κB components can determine whether inflammatory signaling directly regulates CYP4A11 gene expression, potentially creating feedback loops. This multi-faceted approach allows researchers to establish both correlative and causative relationships between CYP4A11-mediated oxidative stress and inflammatory pathway activation.

What experimental design is most effective for studying CYP4A11's role in metabolic syndrome models?

An effective experimental design for studying CYP4A11 in metabolic syndrome requires a multi-level approach integrating in vitro, animal model, and human sample analyses. For in vitro studies, researchers should establish hepatocyte models (such as HepG2 cells) treated with free fatty acids to mimic hepatic steatosis, then modulate CYP4A11 expression through both genetic (overexpression/silencing) and pharmacological (induction/inhibition) approaches . Key outcome measures should include oxidative stress markers (ROS, MDA), inflammatory cytokines (TNF-α, IL-1β, IL-6), and metabolic parameters . For animal models, researchers should compare wild-type and CYP4A11 knockout mice under both normal diet and high-fat diet conditions, assessing metabolic parameters similar to the clinical measurements shown in Table I (BMI, triglycerides, VLDL) . Human sample analysis should involve stratification of subjects based on metabolic syndrome criteria, comparing CYP4A11 expression with clinical parameters as demonstrated in the NAFLD study, where plasma CYP4A11 and lipid peroxidation products showed strong correlation (r=0.86) . This comprehensive approach enables validation of findings across multiple experimental systems, strengthening causal relationships between CYP4A11 activity and metabolic syndrome pathogenesis.